Addie Mazal Peretz, MD
Pain Management · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 13
- 2 carriers
- Office
- 1
Offices
1 location · Stanford Health Care · 3,152 clinicians in this group
Looking this up.
Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
13 plans · 2 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Peretz’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
13 of 13 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence A121979 · Current
Licensed to practise in California · since 2012 · expires 2028-04-30 · New York University School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$28,997
Medicare paid this office $28,997 for 141 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Injection of chemical for paralysis of facial and neck nerve muscles on both sides of face | 49 | $10,772 | $92 |
| New patient visit (60+ min) | 28 | $4,927 | $176 |
| Return visit (30+ min) | 36 | $4,650 | $116 |
| Long return visit (40+ min) | 15 | $2,758 | $172 |
| New patient visit (60+ min) | 18 | $2,723 | $151 |
Who their Medicare patients are
141 Original Medicare patients in 2024. Average age 67 · Under 65 31% · Women 78% · Also on Medicaid 29% · Health risk score 1.29. At or below the middle of the specialty; the typical pain management clinician is at 1.38.
Conditions among them: High blood pressure 53% · Depression 36% · Coronary heart disease 20% · Stroke 20% · Diabetes 18% · Chronic kidney disease 15% · Cancer 14% · COPD 13% · Heart failure 11% · Atrial fibrillation 11%.
The office billed $181,929, Medicare allowed $40,731 and paid $28,997; for 258 services of 10 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 141 | 258 | 67 | 1.29 | $181,929 | $28,997 |
| 2023 | 130 | 242 | 64 | 1.12 | $184,067 | $26,401 |
| 2022 | 133 | 271 | 65 | 1.25 | $202,215 | $27,236 |
| 2021 | 146 | 235 | 65 | 1.12 | $183,641 | $26,249 |
| 2020 | 132 | 187 | 64 | 1.10 | $119,136 | $18,028 |
| 2019 | 81 | 168 | 64 | 1.42 | $87,746 | $12,663 |
| 2018 | 105 | 238 | 66 | 1.17 | $125,823 | $20,985 |
| 2017 | 84 | 138 | 66 | 1.20 | $79,902 | $12,018 |
| 2016 | 51 | 91 | 66 | 1.42 | $54,407 | $9,630 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 4 services
| Injection of chemical for paralysis of facial and neck nerve muscles on both sides of face | 40 | $10,108 | $98 |
| New patient visit (60+ min) | 45 | $7,316 | $163 |
| Long return visit (40+ min) | 41 | $5,128 | $119 |
| Return visit (30+ min) | 32 | $2,742 | $81 |
2022: 4 services
| Injection of chemical for paralysis of facial and neck nerve muscles on both sides of face | 50 | $11,940 | $100 |
| New patient visit (60+ min) | 40 | $5,785 | $145 |
| Long return visit (40+ min) | 40 | $5,749 | $131 |
| Return visit (30+ min) | 20 | $1,452 | $69 |
2021: 4 services
| Injection of chemical for paralysis of facial and neck nerve muscles on both sides of face | 39 | $9,198 | $106 |
| New patient visit (60+ min) | 49 | $7,433 | $152 |
| Long return visit (40+ min) | 36 | $5,150 | $129 |
| Return visit (30+ min) | 22 | $1,767 | $77 |
2020: 4 services
| New patient visit (60+ min) | 43 | $6,059 | $141 |
| Injection of chemical for paralysis of facial and neck nerve muscles on both sides of face | 41 | $4,542 | $87 |
| Long return visit (40+ min) | 34 | $3,197 | $94 |
| Return visit (30+ min) | 15 | $1,040 | $58 |
2019: 5 services
| Injection of chemical for paralysis of facial and neck nerve muscles on both sides of face | 41 | $6,003 | $83 |
| New patient visit (45+ min) | 17 | $1,588 | $93 |
| Injection of anesthetic agent and/or steroid into upper neck and back of head nerve | 11 | $1,455 | $66 |
| Long return visit (40+ min) | 11 | $1,413 | $101 |
| Return visit (30+ min) | 15 | $1,329 | $66 |
2018: 6 services
| Injection of chemical for paralysis of facial and neck nerve muscles on both sides of face | 41 | $7,515 | $93 |
| New patient visit (45+ min) | 32 | $3,458 | $108 |
| Injection of chemical for paralysis of facial and neck nerve muscles on both sides of face | 25 | $2,606 | $100 |
| Injection of anesthetic agent and/or steroid into upper neck and back of head nerve | 14 | $1,833 | $80 |
| Long return visit (40+ min) | 15 | $1,496 | $94 |
| Return visit (30+ min) | 15 | $1,232 | $59 |
2017: 2 services
| Injection of chemical for paralysis of facial and neck nerve muscles on both sides of face | 46 | $6,227 | $94 |
| New patient visit (45+ min) | 23 | $2,378 | $103 |
2016: 3 services
| Injection of chemical for paralysis of facial and neck nerve muscles on both sides of face | 31 | $4,779 | $106 |
| Long return visit (40+ min) | 17 | $1,982 | $99 |
| New patient visit (60+ min) | 12 | $1,797 | $150 |
Medicaid work
$100,259 in 2024
Medicaid paid $100,259 for 292 billed services this clinician did in 2024, up to 21 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Botox | 111 | $89,123 |
| Chemodenervation of muscle(s); muscle(s) innervated by facial, trigeminal, cervical spinal and accessory nerves, bilateral (eg, for chronic migraine) | 181 | $11,137 |
| 2024 | 292 | 2 | 21 | $100,259 |
| 2023 | 85 | 2 | 16 | $25,441 |
| 2022 | 37 | 1 | 13 | $3,699 |
| 2021 | 76 | 1 | 19 | $4,946 |
| 2020 | 26 | 2 | 14 | $3,280 |
| 2019 | 12 | 1 | 12 | $1,595 |
See the largest Medicaid services in earlier years
2023
| Botox | 25 | $20,802 |
| Chemodenervation of muscle(s); muscle(s) innervated by facial, trigeminal, cervical spinal and accessory nerves, bilateral (eg, for chronic migraine) | 60 | $4,639 |
2022
| Chemodenervation of muscle(s); muscle(s) innervated by facial, trigeminal, cervical spinal and accessory nerves, bilateral (eg, for chronic migraine) | 37 | $3,699 |
2021
| Chemodenervation of muscle(s); muscle(s) innervated by facial, trigeminal, cervical spinal and accessory nerves, bilateral (eg, for chronic migraine) | 76 | $4,946 |
2020
| New patient visit (60+ min) | 14 | $1,835 |
| Chemodenervation of muscle(s); muscle(s) innervated by facial, trigeminal, cervical spinal and accessory nerves, bilateral (eg, for chronic migraine) | 12 | $1,444 |
2019
| Chemodenervation of muscle(s); muscle(s) innervated by facial, trigeminal, cervical spinal and accessory nerves, bilateral (eg, for chronic migraine) | 12 | $1,595 |
Drugs they prescribed that Part D paid
$135,219
Pharmacies billed $135,219 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 235) in 2024. At or below the middle of the specialty; the typical pain management clinician is at 44%.
127 generic and 108 brand-name prescriptions · $135,219 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Nurtec Odt | None | 61 | $86,773 | $1,423 |
| Ubrelvy | None | 13 | $13,218 | $1,017 |
| Emgality | Migraine | 11 | $11,746 | $1,068 |
| Ajovy | None | 13 | $10,746 | $827 |
| Rizatriptan | None | 18 | $372 | $21 |
See all 7 drugs
| Nurtec Odt | None | 61 | $86,773 | $1,423 |
| Ubrelvy | None | 13 | $13,218 | $1,017 |
| Emgality | Migraine | 11 | $11,746 | $1,068 |
| Ajovy | None | 13 | $10,746 | $827 |
| Rizatriptan | None | 18 | $372 | $21 |
| Gabapentin | None | 22 | $253 | $11 |
| Memantine | None | 20 | $184 | $9 |
Year by year
| 2024 | 235 | 61 | 0% (0) | 46% | $135,219 |
| 2023 | 166 | 49 | 0% (0) | 46% | $96,814 |
| 2022 | 128 | 32 | 0% (0) | 25% | $35,971 |
| 2021 | 161 | 37 | 0% (0) | 12% | $34,454 |
| 2020 | 80 | 20 | 0% (0) | 23% | $34,814 |
| 2019 | 66 | 14 | 0% (0) | 50% | $26,237 |
| 2018 | 45 | 20 | 0% (0) | None | $3,175 |
| 2017 | 34 | 12 | 0% (0) | 0% | $449 |
| 2016 | 38 | 21 | 0% (0) | 0% | $1,947 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 5 drugs
| Nurtec Odt | None | 37 | $50,362 | $1,361 |
| Emgality | Migraine | 17 | $18,250 | $1,074 |
| Ubrelvy | None | 11 | $10,905 | $991 |
| Rizatriptan | None | 21 | $621 | $30 |
| Gabapentin | None | 19 | $339 | $18 |
2022: 3 drugs
| Nurtec Odt | 17 | $18,858 | $1,109 |
| Rizatriptan | 24 | $787 | $33 |
| Gabapentin | 34 | $278 | $8 |
2021: 4 drugs
| Eletriptan Hbr | 13 | $1,558 | $120 |
| Rizatriptan | 16 | $413 | $26 |
| Promethazine | 38 | $403 | $11 |
| Gabapentin | 19 | $245 | $13 |
2020: 1 drug
| Promethazine | 17 | $62 | $4 |
2019: 1 drug
| Aimovig | Migraine | 24 | $13,942 | $581 |
Money from drug and device companies
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| H. Lundbeck A S · Interventional, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Delayed-Start Study To Evaluate the Efficacy and Safety of Eptinezumab in Patients With Episodic Cluster Headache · 2022 | Their institution | $87,058 |
| H. Lundbeck A S · Eptinezumab in Participants With Episodic Cluster Headache (Alleviate) · 2023 | Their institution | $7,261 |
| H. Lundbeck A S · Eptinezumab in Participants With Episodic Cluster Headache (Alleviate) · 2024 | Their institution | $5,866 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1720387186
- Licence
- CA A121979California A121979: Current · expires 2028-04-30
- Trained
- New York University School of Medicine, 2011
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 2084P2900X (2084P2900X); Neurology (2084N0400X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2011-03-23
- NPI last updated
- 2023-11-10
- NPI record certified
- 2023-11-10
This is when the NPI record was last certified, not a medical board exam.